SEC Form 4 · accession 0001831558-26-000003
Protalix BioTherapeutics, Inc. · PLX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eliot Forster
Director
Period of report
Sep 3, 2026
Accepted (ET)
Sep 4, 2026 · 6:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001006281
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F2,F1 | $2.59 | Sep 3, 2026 | A | 17,000 | A | — | Sep 3, 2036 | Common Stock | 17,000 | 17,000 | D |
| Restricted Stock UnitsF3,F4 | — | Sep 3, 2026 | A | 8,500 | A | — | — | Common Stock | 8,500 | 8,500 | D |
Explanation of responses
- F1The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
- F2Does not include (i) options to purchase 85,715 shares of common stock at an exercise price equal to $1.75 per share that expire on September 14, 2033, and (ii) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
- F3Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
- F4The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.